NCT06873165
Pasteurized Akkermansia Massiliensis LWHK0003 Supplementation in Patients With MASLD
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 11 more changesShow less
- Eligibility criteria shortened, about 138 words
- Trial completed
- Study completion date changed from estimate of Dec 31, 2026 to Dec 30, 2025
- Interventions modified
- Enrollment target: estimated 40 to confirmed 43
- Primary completion date changed from estimate of Dec 31, 2025 to Dec 2, 2025
- Secondary endpoints revised (2)
- Study description expanded, about 132 words
- Site details revised
- Collaborators expanded, about 7 words
- Study title shortened, about 6 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (2)
Arms and interventions
Participants received one matching placebo capsule orally each day for 12 weeks.
Participants received one oral capsule containing pasteurized Akkermansia massiliensis LWHK0003 at a dose of 10⁹ pre-pasteurization colony-forming unit (CFU) equivalents per day for 12 weeks.
Participants received one oral capsule containing pasteurized Akkermansia massiliensis LWHK0003 at a dose of 10¹⁰ pre-pasteurization CFU equivalents per day for 12 weeks.
Participants received one oral capsule containing pasteurized Akkermansia massiliensis LWHK0003 at a dose of 10¹¹ pre-pasteurization CFU equivalents per day for 12 weeks.
Dietary supplements: Pasteurized Akkermansia massiliensis LWHK0003, Placebo
Sites
1 site in 1 country
- National Taiwan University HospitalTaipei, Taiwan